Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations

NCT02070796 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Rotigotine PR2.2.1
DRUG: Rotigotine PR2.1.1

Sponsor

UCB Pharma SA